Alchemia loss grows on lower fondaparinux sales
02 September, 2014 by Dylan Bushell-EmblingAlchemia's (ASX:ACL) share of the profits from sales of anti-coagulant generic fondaparinux declined in FY14, but the company expects business to pick up from 2015.
Imugene names Charles Walker as new CEO
26 August, 2014 by Dylan Bushell-EmblingFormer Alchemia (ASX:ACL) chief Charles Walker has taken the role of Imugene (ASX:IMU) CEO, to help lead the company's efforts to commercialise HER-Vaxx in gastric cancer.
Potential new standard of care for prostate cancer
21 August, 2014A potential new standard of care is emerging for prostate cancer with a new treatment combination significantly reducing the spread of the disease as well as limiting side effects.
Sirtex profit grows 30% in FY14
21 August, 2014 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has posted a 30.6% increase in profit for FY14, as dose sales of its SIR-Spheres liver cancer treatment reached a record high.
Bioscience Managers' first fund achieves 24.7% IRR
15 August, 2014 by Dylan Bushell-EmblingBioscience Managers' first fund returned $1.76 per $1 invested, thanks to its portfolio which includes Alchemia (ASX:ACL) Bionomics (ASX:BNO), Acrux (ASX:ACR) and HeartWare (ASX:HIN).
Novogen lines up a double dose of funding
14 August, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has won shareholder approval to raise funds to bring drug candidates into clinical trials and support from a FSHD foundation for its regenerative program with Genea Biocells.
New malaria vaccine approach attracts collaboration
06 August, 2014 by Susan WilliamsonA collaboration between the Burnet Institute and ARTES Biotechnology will progress the development of and test a new strategy for a malaria vaccine.
UTS boffins develop blood test for oral cancers
29 July, 2014 by Dylan Bushell-EmblingResearchers from UTS have developed a fast and easy way to administer a blood test for detecting early warning signs of oral cancers.
IDT names US distributor for generic cancer drug
29 July, 2014 by Dylan Bushell-EmblingIDT Australia has signed an exclusive distribution deal with Mayne Pharma for melanoma and glioblastoma multiforme treatment generic temozolomide.
Bowel cancer test rolls out in Blue Mountains
28 July, 2014 by Dylan Bushell-EmblingClinical Genomics has launched a trial rollout of its jointly developed blood test for bowel cancer in the Blue Mountains.
Novogen picks CMOs for ovarian cancer drug
28 July, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) joint venture CanTx has chosen two US-based CMOs to manufacture batches of Cantrixil, the ovarian cancer drug candidate it aims to take to the clinic in mid-2015.
Patrys commences CAR T cell research program
24 July, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has started collaborative research into genetically engineering T cells against novel anticancer targets using its IgM antibodies.
Fellowships for research in Japan
24 July, 2014Postdoctoral, short- and long-term research fellowships are available to Australian researchers to work in Japan for 2015-2016.
ImpediMed picks Australian site for L-Dex trial
23 July, 2014 by Dylan Bushell-EmblingImpediMed (ASX:IPD) has named the Macquarie University Cancer Institute as the Australian site for a post-approval trial of L-Dex, its lymphodoema detection device.
Developing guidelines for 'omics'-based tests
23 July, 2014A new guide for 'omics'-based tests, focusing on genomic testing, has been released for public consultation by the NHMRC.
